DexCom, Inc. — FY 2012 Form 10-K
Business context and reporting period. This filing covers the fiscal year ended December 31, 2012; it is an annual report, not a standalone fourth-quarter filing. DexCom develops and sells continuous glucose monitoring (CGM) systems. Its principal products were the SEVEN PLUS and newly launched G4 PLATINUM; it also had an in-hospital product collaboration and acquired diabetes-data software company SweetSpot in March 2012.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Product revenue | $93.0 million | $65.9 million |
| Development grant and other revenue | $6.9 million | $10.4 million |
| Total revenue | $99.9 million | $76.3 million |
| Gross profit | $46.6 million; 46.6% of total revenue | $35.9 million; 47.1% of total revenue |
| Operating expenses | $102.3 million | $80.7 million |
| Operating loss | $55.7 million | $44.8 million |
| Net loss | $54.5 million; $0.79 per share | $44.7 million; $0.68 per share |
| Cash used in operations | $33.1 million | $30.1 million |
| Cash, cash equivalents and short-term securities at year-end | $48.7 million | $82.0 million |
| Working capital | $58.1 million | $89.8 million |
| Debt at year-end | $7.0 million principal, net of $1.0 million unamortized issuance costs on the balance sheet | No long-term debt reported |
Product gross profit was $44.7 million, or approximately 48.1% of product revenue, versus $29.3 million, or approximately 44.5%, in 2011. Capital expenditures were $9.5 million, primarily for manufacturing improvements. Net cash provided by investing activities was $28.4 million, mainly reflecting maturities of marketable securities; financing activities provided $10.2 million.
Fourth-quarter 2012 revenue was $33.3 million, gross profit $17.5 million, total operating costs $25.9 million, and net loss $8.5 million ($0.12 per share). Fourth-quarter 2011 figures were $22.4 million, $10.7 million, $22.9 million, and a $12.2 million net loss ($0.18 per share), respectively.
Material changes versus the prior period
- Total revenue rose 31% year over year, driven by higher CGM system and sensor sales and the G4 PLATINUM U.S. launch in Q4. Product revenue increased $27.1 million.
- Development and other revenue fell $3.5 million, principally because 2011 included a $4.0 million Animas milestone and Edwards collaboration revenue was recognized over a longer period.
- Research and development expense increased $8.7 million to $39.5 million; selling, general and administrative expense rose $12.9 million to $62.8 million. Higher commercialization, staffing, share-based compensation and development costs contributed.
- Net loss increased $9.8 million. The company recorded $2.5 million of excess/obsolete hardware charges associated with the G4 transition, included in a total $3.0 million of noncash inventory and accelerated-depreciation charges described in the cash-flow discussion.
- Cash and short-term securities declined $33.3 million, while working capital fell $31.7 million. The company obtained $7.0 million under a new term loan and reported $6.8 million of long-term debt net of issuance costs, plus $0.2 million current.
Outlook, commentary and key risks
- Management expected continued net losses and increased operating cash use as it expanded commercialization, manufacturing and R&D. It stated that available working capital resources were expected to fund operations through at least December 31, 2013; this is management’s stated expectation, not a guarantee.
- The November 2012 lending agreement provides for a $15 million revolving line (none drawn at year-end) and term loans up to $20 million. $7 million was advanced; up to $13 million more could be requested during June–September 2013. Borrowings are secured by substantially all assets, with a negative pledge on intellectual property, and the facility includes restrictive covenants.
- Medicare had no national coverage decision for CGM. Seven large private payors had coverage policies by February 2013, and DexCom had contracted rates with six, but policies were often restrictive. Reimbursement gaps could constrain adoption and pricing.
- Manufacturing scale-up, product quality and dependence on single-source suppliers are significant risks. Edgepark accounted for approximately 15% of FY 2012 revenue. DexCom also reported prior brief supply constraints and sensor-related field failures, including reports of broken or lodged sensors.
- Abbott patent litigation remained stayed pending patent-office proceedings. The company said the outcome and potential costs could not be assessed and recorded no litigation accrual at year-end. An adverse outcome could impair sales of products using the disputed technology.
- G4 PLATINUM received FDA approval in October 2012 and began U.S. commercialization in Q4; the G4 system received CE Mark approval in June 2012. Management planned to reduce SEVEN PLUS marketing as G4 adoption progressed. GlucoClear had limited European commercialization; Edwards planned a limited second-generation launch in 2013.
- Subsequent events: Tandem’s agreement was amended in January 2013 to integrate G4 PLATINUM. Roche notified DexCom in February 2013 that it was terminating its agreement; DexCom expected $0.6 million of previously received consideration to be recognized in Q1 2013 and forfeited eligibility for up to $2.0 million of Roche milestones.
- The filing notes an annual 2.3% medical-device excise tax beginning in 2013; then-current IRS guidance excluded the existing SEVEN PLUS and G4 PLATINUM products as retail medical devices. The impact on potential future products was unclear.
Most important facts for investors to verify
- Whether G4 PLATINUM sales growth, sensor usage and gross-margin improvement continued after the initial Q4 launch.
- Whether cash burn, liquidity and financing availability align with management’s funding-through-2013 expectation, including loan covenants and any additional borrowing.
- Progress in manufacturing capacity, product reliability, supplier continuity and resolution of reported sensor failures.
- Expansion of private-payor coverage, reimbursement terms and customer concentration, including the ongoing importance of Edgepark.
- Developments in Abbott litigation and patent reexaminations, and any resulting exposure to injunctions, licensing costs or operational restrictions.
- Commercial and regulatory progress for SweetSpot, Tandem integration, pediatric indications and GlucoClear, including the effect of Roche’s termination.